Cg Oncology, Inc. · NASDAQ:CGON
Cg Oncology — Technical Presentation (October 2025)
14 slides from Cg Oncology's technical presentation, Oct 16, 2025
Slide 1: Encore Durability Results From BOND-003 Cohort C
Encore Durability Results From Bond-003 Cohort C: Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for High- Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma In Situ For individual reference only. The information accessed through this QR code is intended solely
Slide 2: Disclosures
Disclosures • CG Oncology – No conflicts of Interests 2
Slide 3: Cretostimogene Grenadenorepvec Selectively Targets Rb-E2F Pathway Altered Cancers
Cretostimogene Grenadenorepvec Selectively Targets Rb-E2F Pathway Altered Cancers • Conditionally replicating, highly immunogenic adenovirus o Under regulation of the human E2F-1 promoter - Selective for RB-E2F pathway alterations o Encodes GM-CSF transgene • Oncolytic immunotherapy with dual MOA o
Slide 4: Phase 3 Cretostimogene Monotherapy for High-Risk BCG-Unresponsive NMIBC with CIS
Phase 3 Cretostimogene Monotherapy for High-Risk BCG-Unresponsive NMIBC with CIS HR BCG-Unresponsive NMIBC Cretostimogene Grenadenorepvec Primary Endpoint: Single-Arm, Open-Label, IVE Administration CR at Any Time Population Study Design / Regimen Additional Endpoints • Enrollment complete (n=112) •
Slide 5: Patient Demographics & Baseline Characteristics
Patient Demographics & Baseline Characteristics Subjects in Safety Dataset N=112 % Gender Male 83 74.1 • Majority of patients are: Female 29 25.9 o Male (74%) Legend Age (Years) Mean (SD) 72.9 (9.19) o White (62%) Median (Range) 74.0 (43-90) o > 65 years (83%) Age (Categories) < 65 19 17.0 IVE gem ≥
Slide 6: Consistent and Compelling CR & 24-Month Durability Data
Consistent and Compelling CR & 24-Month Durability Data Overall Complete Response CR CR Rate, % CR by K-M Est, % 75.5% 100 Landmark (95% CI) (95% CI) (95% CI, 66.3 % - 83.2 %) Legend 12-month 46.4% (36.9, 56.1) 50.7% (40.9, 59.8) 75 51 out of 110 patients Overall CR Rate (%) 41.8% (32.5, 51.6) IVE g
Slide 7: Cretostimogene Demonstrates Best in Class Duration of Response in HR BCG-UR NMIBC
Cretostimogene Demonstrates Best in Class Duration of Response in HR BCG-UR NMIBC Estimated DOR Probability at 12 Months Estimated DOR Probability 64.1% at 24 Months Duration of Response Probability (%) (95% CI: 52.4-73.7) 58.3% (95% CI: 46.3-68.5) • Median DoR is 27.9 months and ongoing (95% CI 14.
Slide 8: Sustained Responses Observed Over 45 Months
Sustained Responses Observed Over 45 Months • 50.0% of patients reinduced with oncolytic immunotherapy converted to CR o 64.3% remain in durable response after conversion to CR • Patients remain in response after treatment completion Efficacy data cutoff as of 14MAR2025. 1 Per 2018 FDA Guidance Docu
Slide 9: High CR Rate Consistent Across Patient Subgroups, Including Prior Chemotherapy
High CR Rate Consistent Across Patient Subgroups, Including Patients Treated with Prior Chemotherapy Complete Response Rate (95% CI) 9
Slide 10: Favorable and Well-Tolerated Safety Profile
Favorable and Well-Tolerated Safety Profile Cretostimogene (n=112) Preferred Term (MedDRA v.26.1) Any Grade (%) Grade ≥ 3 • Most AEs were Grade 1-2 Patients with ≥ 1 TRAE 71 (63.4%) 0 (0) • 0% Grade ≥ 3 TRAEs or deaths Treatment-Related AE reported in > 10% patients • Median time to TRAE resolution:
Slide 11: Viral Replication and Transgene Expression
Viral Replication and Transgene Expression Pre-Dose Creto Titer Pre-Dose GM-CSF Post-Dose Creto Titer Post-Dose GM-CSF 1000 108 • Cretostimogene replication and GM-CSF expression are linked 107 Cretostimogene Titer in Urine • Urine levels peak immediately (Genome Copy Number/mL) GM-CSF in Urine (pg/
Slide 12: Key Takeaways
Key Takeaways • Highly effective and very well-tolerated regimen • Best in class durability and tolerability • Robust and stable anti-tumor response • Heavily pre-treated BCG-UR CIS containing cohort • Scalable within existing clinic workflow; administered by MAs & RNs • Future and ongoing clinical
Slide 13: First Results: BOND-003 Cohort P HR NMIBC BCG-Unresponsive HG Ta/T1
First Results: BOND-003 Cohort P HR NMIBC BCG- Unresponsive HG Ta/T1 Kaplan-Meier Estimate for High Grade Recurrence-Free Survival • Data from first 24 treated patients • Strong early responses with HG Recurrence-Free Survival (%) 90.5% HG-RFS (95% CI: 77.9-100%) at 3 and 9 Months • Very well-tolera
Slide 14: Thank You
Thank You All Bladder Cancer Patients and Their Families Key Investigators, Study Coordinators, Nurses Key Collaborators CG Oncology For individual reference only. The information accessed through this QR code is intended solely for individual Mark Tyson, Mayo, AZ Andy Darilek reference and should n